Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer

다국어 초록 (Multilingual Abstract)

Purpose: The interaction of programmed death receptor 1 (PD-1) and its ligand, programmed death receptor ligand 1 (PD-L1), negatively regulates immune responses. This study aimed to clarify PD-L1 expression levels in breast cancer through immunohistochemistry (IHC) and to evaluate associations between these findings and clinicopathologic variables, including prognosis. Methods: PD-L1 expression was analyzed using IHC on tissue microarrays of 465 invasive breast carcinomas. Results: High PD-L1 expression was demonstrated in 63 of 465 tumors (13.5%). High PD-L1 expression was significantly associated with high histologic grade (p<0.001), negative lymph nodes (p=0.011), early pathologic stage (p=0.025), high tumor-infiltrating lymphocyte (TIL) (p<0.001) counts, negative estrogen receptor (p<0.001) and progesterone receptor (p=0.002) expression, positive human epidermal growth factor receptor 2 (HER2) (p=0.003), cytokeratin 5/6 (p=0.011), epidermal growth factor receptor (p<0.001), and p53 (p<0.001) expression, and high Ki-67 proliferating index (p<0.001). Based on intrinsic subtypes, high PD-L1 expression and high TIL counts were significantly associated with the HER2 and triple-negative basal type (p<0.001). PD-L1 expression was significantly associated with better disease-free survival (DFS) (p=0.041) and overall survival (OS) (p=0.026) in the univariate analysis, but not in the multivariate analysis. Higher TIL levels was an independent prognostic factor for decreased disease progression (hazard ratio [HR], 2.389; 95% confidence interval [CI], 1.284–4.445; p=0.006) and overall death (HR, 3.666; 95% CI, 1.561–8.607; p=0.003). Conclusion: PD-L1 protein expression in breast cancer is associated with better DFS and OS, but is not an independent prognostic factor. High PD-L1 expression was significantly associated with high TIL levels. This finding has important implications for antibody therapies targeting the PD-1/PD-L1 signaling mechanism in breast cancer.

참고문헌 (Reference)

1 Hino R, "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma" 116 : 1757-1766, 2010

2 Salgado R, "The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014" 26 : 259-271, 2015

3 Ghebeh H, "The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors" 8 : 190-198, 2006

4 Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer" 366 : 2443-2454, 2012

5 Velcheti V, "Programmed death ligand-1 expression in non-small cell lung cancer" 94 : 107-116, 2014

6 Eto S, "Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection" 19 : 466-471, 2016

7 Gatalica Z, "Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type" 23 : 2965-2970, 2014

8 Baptista MZ, "Prognostic significance of PD-L1 and PD-L2 in breast cancer" 47 : 78-84, 2016

9 Sabatier R, "Prognostic and predictive value of PDL1 expression in breast cancer" 6 : 5449-5464, 2015

10 Ali HR, "PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes" 26 : 1488-1493, 2015

11 Soliman H, "PD-L1 expression is increased in a subset of basal type breast cancer cells" 9 : e88557-, 2014

12 Mittendorf EA, "PD-L1 expression in triple-negative breast cancer" 2 : 361-370, 2014

13 Lipson EJ, "PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival" 1 : 54-63, 2013

14 Wimberly H, "PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer" 3 : 326-332, 2015

15 Wu P, "PD-L1 and survival in solid tumors:a meta-analysis" 10 : e0131403-, 2015

16 Cimino-Mathews A, "PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas" 47 : 52-63, 2016

17 Keir ME, "PD-1 and its ligands in tolerance and immunity" 26 : 677-704, 2008

18 Bour-Jordan H, "Intrinsic and extrinsic control of peripheral Tcell tolerance by costimulatory molecules of the CD28/ B7 family" 241 : 180-205, 2011

19 Schalper KA, "In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas" 20 : 2773-2782, 2014

20 Cimino-Mathews A, "Immune targeting in breast cancer" 29 : 375-385, 2015

21 Mu CY, "High expression of PDL1in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation" 28 : 682-688, 2011

22 장시형, "High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer" 한국유방암학회 19 (19): 53-60, 2016

23 Oliveira-Costa JP, "Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells" 6 : 20902-20920, 2015

24 Muenst S, "Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer" 146 : 15-24, 2014

25 Ghebeh H, "Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells" 121 : 751-758, 2007

26 Phillips T, "Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer" 23 : 541-549, 2015

27 Taube JM, "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape" 4 : 127-137, 2012

28 Shin SJ, "Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma:association with oncogenic proteins status" 23 : 694-702, 2016

29 Droeser RA, "Clinical impact of programmed cell death ligand 1 expression in colorectal cancer" 49 : 2233-2242, 2013